StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Alexion Pharma (ALXN) Phase 3 REGAIN Study of Eculizumab Did Not Reach Statistical Significance
June 6, 2016 4:03 PM
Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) today announced topline results from the REGAIN study, a Phase 3 registration trial of eculizumab ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Corporate News
FDA
Hot Corp. News
Hot FDA News
Next Articles
Oppenheimer Cuts Price Target on Alexion Pharma (ALXN) Following Data Release
June 7, 2016 9:46 AM
Alexion (ALXN) Buy On Weakness - Piper Jaffray
June 7, 2016 9:29 AM
Alexion Pharmaceuticals (ALXN) PT Lowered to $186 at Credit Suisse
June 7, 2016 8:38 AM
Alexion Pharma (ALXN): MG P3 Miss Increases Importance of ALXN-1210; PT to $160 - BMO
June 7, 2016 6:18 AM
Alexion Pharma (ALXN) Sinks 9% as Trading Resumes
June 6, 2016 4:35 PM
Alexion Pharma (ALXN) to Resume Trading at 4:30PM Following Trial Failure
June 6, 2016 4:14 PM
Alexion Announces Topline Results from Phase 3 REGAIN Study of Eculizumab (Soliris®) in Patients with Refractory Generalized Myasthenia Gravis (gMG)
June 6, 2016 4:01 PM
